T‐Cell Immunotherapy for Adenoviral Infections of Stem‐Cell Transplant Recipients
暂无分享,去创建一个
H. Heslop | C. Rooney | C. Bollard | A. Gee | A. Leen | U. Sili | M. H. Huls | G. D. Myers | A. Leen
[1] E. Claas,et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery , 2005, Bone Marrow Transplantation.
[2] H. Heslop,et al. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation. , 2005, Cytotherapy.
[3] M. Schilham,et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. , 2005, The Journal of infectious diseases.
[4] R. Handgretinger,et al. Detection of adenovirus‐specific T cells in children with adenovirus infection after allogeneic stem cell transplantation , 2005, British journal of haematology.
[5] C. Rooney,et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. , 2004, Blood.
[6] L. Eisenlohr,et al. Adenovirus hexon T-cell epitope is recognized by most adults and is restricted by HLA DP4, the most common class II allele , 2004, Gene Therapy.
[7] S. Mackinnon,et al. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. , 2004, Human immunology.
[8] C. Fegan,et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] C. Rooney,et al. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. , 2004, Blood.
[10] F. Watzinger,et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. , 2003, Blood.
[11] M. Schilham,et al. Extensive Cross-Reactivity of CD4+ Adenovirus-Specific T Cells: Implications for Immunotherapy and Gene Therapy , 2003, Journal of Virology.
[12] M. Horwitz,et al. The impact of adenovirus infection on the immunocompromised host , 2003, Reviews in medical virology.
[13] A. Davis,et al. Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy , 2003, Journal of immunotherapy.
[14] Y. Osugi,et al. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. , 2002, Blood.
[15] C. Fegan,et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. , 2002, Blood.
[16] L. Eisenlohr,et al. The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope. , 2002, Human gene therapy.
[17] P. Gavin,et al. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. , 2002, Pediatrics.
[18] A. Fischer,et al. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. , 2002, Human Gene Therapy.
[19] E. Bloemena,et al. Identification and prevalence of CD8+ T‐cell responses directed against Epstein‐Barr virus‐encoded latent membrane protein 1 and latent membrane protein 2 , 2002, International journal of cancer.
[20] Z. Ruzsics,et al. Subversion of host defense mechanisms by adenoviruses. , 2002, Current topics in microbiology and immunology.
[21] E. Bloemena,et al. Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+ T-Helper 1 Responses , 2001, Journal of Virology.
[22] N. Kapoor,et al. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[23] A. Davis,et al. Efficient infection of primitive hematopoietic stem cells by modified adenovirus , 2001, Gene Therapy.
[24] L. Eisenlohr,et al. Quantitative analysis of adenovirus-specific CD4+ T-cell responses from healthy adults. , 2001, Viral immunology.
[25] A. Lieber,et al. Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain , 2000, Journal of Virology.
[26] G. Stamatoyannopoulos,et al. Efficient Gene Transfer into Human CD34+ Cells by a Retargeted Adenovirus Vector , 2000, Journal of Virology.
[27] W. Wold,et al. Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic. , 1999, Current opinion in immunology.
[28] V. Calcaterra,et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.
[29] H. Heslop,et al. Adenovirus infection after pediatric bone marrow transplantation , 1999, Bone Marrow Transplantation.
[30] D. Srivastava,et al. Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients , 1998 .
[31] A. Elsing,et al. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Rooney,et al. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. , 1998, Human gene therapy.
[33] S. Riddell,et al. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate–early gene product , 1996, Nature.
[34] C. Rooney,et al. Adenovirus-pulsed dendritic cells stimulate human virus-specific T-cell responses in vitro , 1996, Journal of virology.
[35] Malcolm K. Brenner,et al. Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes , 1996, Nature Medicine.
[36] S. Riddell,et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.
[37] R. Truitt,et al. Characterization of human proliferative T cell responses to adenovirus. , 1995, The Journal of infectious diseases.
[38] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[39] M. Horowitz,et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. , 1994, The Journal of infectious diseases.
[40] W. Wold,et al. Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. , 1991, Virology.
[41] J. Haskill,et al. Human monocyte inflammatory mediator gene expression is selectively regulated by adherence substrates. , 1989, Journal of immunology.
[42] S. Haskill,et al. Adherence induces selective mRNA expression of monocyte mediators and proto-oncogenes. , 1988, Journal of immunology.
[43] H. Burgert,et al. The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition. , 1987, The EMBO journal.
[44] K. Anderson,et al. Adenovirus early region 1A modulation of interferon antiviral activity , 1987, Journal of virology.